Nosco Blog

Nosco Enters into Pharmaceutical 503B Market


Topics: Packaging Printing pharmaceutical 503B Pharmaceutical 503B

Innovative Printed Packaging Provider Announces the Addition of Dedicated Market Leader and Packaging Advisor to Support New Pharmaceutical 503B Market Endeavors

Nosco, Inc., a subsidiary of Holden Industries, Inc., recently announced its entry into the pharmaceutical 503B market, as well as the addition of dedicated 503B Market Leader and Packaging Advisor, Christy Cornelius. Through her 20+ years of experience in the pharmaceutical and 503B markets, Cornelius appreciates the importance of understanding 503B rules and regulations – especially when it comes to packaging.



“We are pleased to welcome Christy to Nosco’s team of employee owners,” said Nosco’s Sr. VP of Sales and Marketing Craig Curran. “She is joining our team at an exciting time, as we expand into the pharmaceutical 503B market.”

Throughout her career, Cornelius gained experience in sourcing, forecasting, planning through to distribution, inventory and warehousing, cGMP compliance and 503B compounding. In her role at Nosco, she will leverage her knowledge to drive successful packaging solutions ­– supporting customers with labels, cartons, inserts and more. 

In addition to Cornelius’ market expertise, customers will also benefit from Nosco’s longstanding experience in the pharmaceutical industry. “Nosco is responsible, accountable, respectful, effective and regulatory-compliance efficient,” said Cornelius. “We promote honesty and integrity, while encouraging innovation to meet challenges.”

Cornelius holds certifications from the Pharmacy Technician Certification Board, Texas State Board of Pharmacy, Accreditation Council for Pharmacy Education, and Essentials of Communicating with Diplomacy and Professionalism. Additionally, Nosco is a member of the International Society for Pharmaceutical Engineering (ISPE) and the International Academy of Compounding Pharmacists (IACP). 

To learn more about Nosco’s products and services, including pharmaceutical 503B-compliance, visit